Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study
Importance Atezolizumab (anti–programmed cell death ligand 1 [PD-L1]) is well tolerated
and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple-
negative breast cancer (mTNBC) has not been reported. Objective To evaluate the safety,
clinical activity, and biomarkers associated with the use of single-agent atezolizumab in
patients with mTNBC. Design, Setting, and Participants Women with mTNBC (defined by
investigator assessment) were enrolled between January 2013 and February 2016 in a …
and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple-
negative breast cancer (mTNBC) has not been reported. Objective To evaluate the safety,
clinical activity, and biomarkers associated with the use of single-agent atezolizumab in
patients with mTNBC. Design, Setting, and Participants Women with mTNBC (defined by
investigator assessment) were enrolled between January 2013 and February 2016 in a …